ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

584

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Gastric Cancer
Interventions
DRUG

Trastuzumab

Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression

DRUG

Fluorouracil

800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles

DRUG

Cisplatin

80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles

DRUG

Capecitabine

1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles

Trial Locations (142)

11

Lima

18

Lima

500

Changhua

807

Kaohsiung City

1925

Cape Town

2217

Sydney

2730

Herlev

3000

Leuven

3128

Melbourne

4064

Milton

4091

Durban

4700

Braga

5000

Odense

5011

Adelaide

5037

Kurralta Park

6008

Perth

7506

Cape Town

8000

Faro

10103

San José

13273

Marseille

14000

Mexico City

14076

Caen

17007

Girona

28041

Madrid

29609

Brest

33100

Udine

33520

Tampere

34300

Istanbul

35100

Izmir

35340

Izmir

41014

Valencia

43100

Parma

44280

Guadalajara

46009

Valencia

50139

Florence

51092

Reims

54290

Trier

55101

Mainz

58455

Witten

59020

Lille

60121

Ancona

64020

Monterrey

67098

Strasbourg

68024

Colmar

69120

Heidelberg

76031

Rouen

80131

Napoli

81675

München

97500

Mérida

100021

Beijing

100036

Beijing

100071

Beijing

100853

Beijing

115478

Moscow

117837

Moscow

125284

Moscow

129128

Moscow

150054

Yaroslavl

153040

Ivanovo

195067

Saint Petersburg

197022

Saint Petersburg

197758

Saint Petersburg

200003

Shanghai

200025

Shanghai

200032

Shanghai

200080

Shanghai

200092

Shanghai

200433

Shanghai

210002

Nanjing

210009

Jiangsu

215006

Suzhou

390011

Ryazan

400026

Mumbai

420029

Kazan'

430030

Wuhan

443031

Samara

450054

Ufa

510060

Guangzhou

510515

Guangdong

620905

Yekaterinburg

682304

Kochi

14784-400

Barretos

20231-050

Rio de Janeiro

04023-900

São Paulo

05403-010

São Paulo

Unknown

San José

Panama City

Callao

Seoul

Istanbul

01015

Guatemala City

500 033

Hyderabad

110 029

New Delhi

00168

Roma

464-8681

Aichi

277-8577

Chiba

791-0280

Ehime

812-8582

Fukuoka

650-0017

Hyōgo

384-0392

Nagano

569-8686

Osaka

589-8511

Osaka

350-1298

Saitama

362-0806

Saitama

411-8777

Shizuoka

320-0834

Tochigi

113-8677

Tokyo

135-8550

Tokyo

135-8577

Tokyo

990-8520

Yamagata

06760

Mexico City

3000-075

Coimbra

4810-055

Guimarães

1099-023

Lisbon

1649-035

Lisbon

4099-001

Porto

4200-072

Porto

4200-319

Porto

454 087

Chelyabinsk

420-021

Buchun

463-802

Bundang City

702-210

Daegu

410-769

Goyang-si

602-715

Pusan

110-744

Seoul

120-752

Seoul

135-170

Seoul

135-720

Seoul

138-736

Seoul

08036

Barcelona

08041

Barcelona

08907

Barcelona

00112

Taipei

06100

Shhiye, Ankara

B9 5SS

Birmingham

LL18 5UJ

Denbigh

DD1 9SY

Dundee

G12 0YN

Glasgow

M2O 4BX

Manchester

CH63 4JY

Metropolitan Borough of Wirral

BS23 4TQ

Weston-super-Mare

WV10 0QP

Wolverhampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Chugai Pharmaceutical

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY